Emavusertib

Phase 2Biologic

NNational Cancer Institute (NCI)

Emavusertib is one of 269 biologic programs targeting Central Nervous System Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

268

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Nervous System LymphomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Biliary Tract CancerActive, not recruiting

AnemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Pancreatic CancerActive, not recruiting

Acute Myeloid LeukemiaRecruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Metastatic Colorectal AdenocarcinomaRecruiting

Metastatic Urothelial CarcinomaRecruiting

Central Nervous System LymphomaPhase 1/Phase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Biliary Tract CancerPhase 1

Active, not recruiting

AnemiaPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Metastatic Colorectal AdenocarcinomaPhase 1

Recruiting

Metastatic Urothelial CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Emavusertib

NNational Cancer Institute (NCI)

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

Merck & Co.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

LDE225

Novartis

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

Thiazolidinediones

Sanofi

Preclinical

1 9

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 10

Meglitinides

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Central Nervous System Lymphoma

NCT03328078

Phase 1Recruiting

Metastatic Colorectal Adenocarcinoma

NCT06696768

Q2 2027

Phase 1Recruiting

Metastatic Urothelial Carcinoma

NCT06439836

Q4 2027

Phase 2Recruiting

Chronic Lymphocytic Leukemia

NCT07271667

Phase 2Not yet recruiting

Anemia

NCT07463820

Q2 2029

Phase 2Recruiting

Acute Myeloid Leukemia

NCT05564390

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05685602·43 enrolled

Anemia1 trial

A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07463820·270 enrolled

Biliary Tract Cancer1 trial

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07107750·48 enrolled

Central Nervous System Lymphoma1 trial

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Recruiting·CCuris, Inc.·Phase 1/2·NCT03328078·152 enrolled

Myelodysplastic Syndrome1 trial

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Suspended·CCuris, Inc.·Phase 1/2·NCT04278768·366 enrolled

4 more indications

Chronic Lymphocytic Leukemia1 trial

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Recruiting·CCuris, Inc.·Phase 2·NCT07271667·108 enrolled

Acute Myeloid Leukemia1 trial

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

Metastatic Colorectal Adenocarcinoma1 trial

Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06696768·24 enrolled

Metastatic Urothelial Carcinoma1 trial

Phase 1 Trial of CA-4948 in Combination With Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06439836·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Emavusertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Emavusertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Emavusertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Emavusertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q2 2029

Trials by Indication[1]

Pancreatic Cancer1 trial

Anemia1 trial

Biliary Tract Cancer1 trial

Central Nervous System Lymphoma1 trial

Myelodysplastic Syndrome1 trial

Chronic Lymphocytic Leukemia1 trial

Acute Myeloid Leukemia1 trial

Metastatic Colorectal Adenocarcinoma1 trial

Metastatic Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News